Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.

By Vivek Y. Reddy, H. Sievert, J. Halperin, S. Doshi, M. Buchbinder, P. Neužil, K. Huber, B. Whisenant, Saibal Kar, V. Swarup and 2 more. Journal of the American Medical Association (JAMA), 2014

935 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/c74044c139407d7a0c91016910044be6fb54a372

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Vivek Y. Reddy
2. S. Doshi
3. P. Neužil
4. David R. Holmes III
5. Saibal Kar
6. M. Buchbinder
7. K. Huber
8. M. Price

Citations in the corpus

• 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. (2017, methodology): “However, a high complication rate prompted initiation of a second randomized trial, PREVAIL (Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy), which maintained a similar design to PROTECT AF with slight modifications to the inclusi”